Morgan Stanley’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Morgan Stanley’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1	Closed	-$18	–	8142
2023 Q4	$18	Hold	1	–	–	﹤0.01%	7764
2023 Q3	$13	Hold	1	–	–	﹤0.01%	7552
2023 Q2	$60	Hold	1	–	–	﹤0.01%	7530
2023 Q1	$359	Hold	1	–	–	﹤0.01%	7468
2022 Q4	$2.38K	Sell	1 -1	-50%	-$3.41K	﹤0.01%	7323
2022 Q3	$12K	Buy	2 +1	+100%	+$21K	﹤0.01%	7028
2022 Q2	$8K	Hold	1	–	–	﹤0.01%	7301
2022 Q1	$26K	Hold	1	–	–	﹤0.01%	7035
2021 Q4	$22K	Buy	+1	New	+$46.3K	﹤0.01%	7195
2021 Q3	–	Hold	0	–	–	–	7208
2021 Q2	–	Hold	0	–	–	–	7330
2021 Q1	–	Hold	0	–	–	–	6957
2020 Q4	–	Hold	0	–	–	–	6476

Morgan Stanley's PBLA Position: Q1 2024 in Review

Morgan Stanley sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2024, closing a stake of 1 share — an estimated $18 sold.

Morgan Stanley first reported a position in PBLA in Q4 2021 and held it in 9 quarters. The position peaked at $26K in Q1 2022. 0 funds tracked by Wall St. Rank hold PBLA as of Q1 2024.

Morgan Stanley reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Morgan Stanley sold 1 Panbela Therapeutics, Inc. Common Stock share in Q1 2024, an estimated $18.
Morgan Stanley first reported a position in Panbela Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Morgan Stanley's Panbela Therapeutics, Inc. Common Stock position peaked at $26K in Q1 2022.
0 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.